Acadia gets major external financing boost  

Danish-American biotech company Acadia Pharmaceuticals receives DKK 173 million in external finance

Danish-American biotech company Acadia Pharmaceuticals has received DKK 173 million (USD 25 million) in external financing reports Oxford Bioscience Partners in Westport Connecticut is the principal investor, others including OrbiMed Advisors, Federated Kaufmann Fund, LD Pensions, Hambrecht & Quist Capital Management LLC, ABN AMRO Ventures, Carnegie Fund II Biotechbridge and Dansk Kapitalanlæg.


Acadia Pharmaceuticals is a drug discovery and development company that identifies low molecular weight target-specific drug candidates. The new capital will be used for clinical testing of these therapeutic hopefuls. The company focuses on drug development for conditions such as Parkinson's Disease, psychosis, chronic pain and glaucoma. Acadia has its chemical research facilities in Glostrup near Copenhagen, and its headquarters and biological research facilities in San Diego, California.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×